Background and Purpose: 4D contrast-enhanced MRA in the follow-up of treated dural arteriovenous fistulas has rarely been evaluated. Our aim was to evaluate its diagnostic performance at 3T in the follow-up of embolized dural arteriovenous fistulas using DSA as the standard of reference.

Materials and Methods: Patients treated for dural arteriovenous fistulas in 2 centers between 2008 and 2019 were included if they met the following criteria: 1) dural arteriovenous fistula embolization, and 2) follow-up imaging with <6 months between DSA and 4D contrast-enhanced MRA. Two readers reviewed the 4D contrast-enhanced MRA images, first independently, then in consensus to detect any residual/recurrent dural arteriovenous fistula and to grade cases according to the Cognard classification system. Interobserver and intermodality agreement for the detection of a residual dural arteriovenous fistula and stratification of bleeding risk (0-I-IIa: 1-IIb-IIa+b-III-IV-V) was calculated using κ coefficients.

Results: A total of 51 pairs of examinations for 44 patients (median age, 65 years; range, 25–81 years) were analyzed. Interobserver agreement for the detection and stratification of bleeding risk was, respectively, κ = 0.8 (95% CI, 0.6–1) and κ = 0.8 (95% CI, 0.5–1). After consensus review, the sensitivity and specificity of 4D contrast-enhanced MRA for the detection of residual/recurrent dural arteriovenous fistula was 63.6% (95% CI, 40.7–82.8%) and 96.6% (95% CI, 82.2–99.9%), respectively. The positive and negative predictive values of 4D contrast-enhanced MRA were 93.3% (95% CI, 68.1–99.8%) and 77.8% (95% CI, 60.8–89.9%). Intermodality agreement for the detection and stratification of bleeding risk was good, with κ = 0.60 (95% CI, 0.3–0.8).

Conclusions: 4D contrast-enhanced MRA at 3T is of interest in the follow-up of treated dural arteriovenous fistulas but lacks the sensitivity to replace arteriography.

Abbreviations: DAVF = dural arteriovenous fistula; 4D-MRA = 4D contrast-enhanced magnetic resonance angiography.
phase venous filling. 4D contrast-enhanced MRA (4D-MRA) was conceived to solve this problem and provide better temporal resolution while also preserving spatial resolution. With improving technology, it became a widely used technique with the advantage of a dynamic DSA-like evaluation of DAVFs. Previous studies report time-resolved 3T MR angiography as an appropriate tool for DAVF diagnosis and monitoring. However, the value of 4D-MRA for the follow-up of patients with treated DAVFs has rarely been evaluated.

We hypothesized that this technique could be valuable for the follow-up and posttherapeutic assessment of DAVFs. With DSA images as the standard of reference, the purpose of this study was to evaluate the performance of 4D-MRA at 3T in the follow-up of patients with treated DAVFs.

MATERIALS AND METHODS

Study Design

Institutional review board approval was granted (No. 19.87), and informed consent was waived due to the study design. All patients treated for DAVFs in 2 university hospital departments (Rennes and Brest, France) were included in a data base. For this study, patients imaged between August 2008 and May 2019 were included if they met the following criteria:

1. They had a DAVF treated with embolization
2. They underwent both 4D-MRA at 3T and DSA during follow-up
3. Both examinations were performed within a 6-month interval without treatment between them.

Treatment Strategy

For all patients, the indication and strategy of treatment were based on multidisciplinary decisions involving neurologists, neurosurgeons, and neuroradiologists.

MR Imaging

All MRA examinations were performed on a 3T MR imaging system (Achieva and Ingenia, Philips Healthcare, Best, Netherlands). All contrast-enhanced 4D-MRA examinations consisted of coronal, sagittal, and axial MIP subtraction images derived from a sagittal time-resolved 3D T1-weighted fast gradient-echo sequence. Several acquisition schemes were used according to the brain coverage (full or two-thirds). At least 20 dynamic acquisitions were performed with a temporal resolution of 0.9–1.7 seconds per volume and a native spatial resolution from 0.8 × 0.8 × 1.6 mm³ to 1.1 × 1.1 × 2.8 mm³ and, after interpolation, ranging from 0.5 × 0.5 × 0.9 mm³ to 0.94 × 0.94 × 1.4 mm³. The 15-mL macrocyclic gadolinium bolus was administered intravenously at a minimum rate of 3 mL/s.⁷

DSA Technique

DSA was performed on a biplane angiography system (Allura, Philips Healthcare, Best, Netherlands and Artis, Siemens Healthineers, Erlangen, Germany). DSA images involved selective injection of internal and external carotid and vertebral arteries with anterior-posterior and lateral projections, supplemented by additional views when necessary. Each projection was acquired with a frequency of 2–3 images per second. For each projection, a 6- to 10-mL bolus of nonionic iodinated contrast material was injected with a power injector.

End Points

The primary end point was to evaluate the diagnostic reproducibility and performance of 4D-MRA for detecting any residual/recurrent shunts in patients with treated DAVFs using DSA as the standard of reference. The secondary end point was to evaluate the diagnostic reproducibility and performance of 4D-MRA for detecting any high-bleeding-risk residual/recurrent shunts in patients with treated DAVFs using DSA as the standard of reference.

Interpretation

Readers were blinded to all clinical data except the original location of the treated DAVF. Only the 3 MIPs were used to read the 4D-MRA. One reader (J.-C.F., reader 3) with 17 years’ experience in neuroradiology reviewed the DSA images. Two readers (F.E., reader 1, and B.D., reader 2) with 9 and 5 years’ experience in neuroradiology, respectively, reviewed the 4D-MRA images. First, readers 1 and 2 assessed the quality of the 4D-MRA images. 4D MRA image-quality scores ranged among 0 (no vascular study possible), 1 (vascular study possible with low diagnostic confidence), 2 (vascular study possible with adequate diagnostic confidence), and 3 (vascular study possible with high diagnostic confidence). The readers independently assessed the presence of residual/recurrent DAVFs on the 4D-MRA and DSA images. Then, when present, each DAVF was graded according to the Cognard classification scheme and divided into 2 groups based on bleeding risk: low-bleeding-risk DAVFs (types I and IIa) and high-bleeding-risk DAVFs (types IIb, IIa + b, III, IV, and V).⁵ Second, a consensus reading (readers 1 and 2) of the 4D-MRA images was conducted to solve any discrepancies. Third, a retrospective explanatory analysis was performed in consensus by the 3 readers to explain intermodality (4D-MRA and DSA) differences.

Data Analysis and Sample Size

Baseline characteristics, including age and fistula type, were summarized using descriptive statistics. The intervals among DSA and 4D-MRA, treatment, and the first imaging technique (DSA or 4D-MRA) were recorded. 4D-MRA interobserver and intermodality agreement was assessed using κ for the following: 1) residual/recurrent DAVF detection, and 2) bleeding-risk grading with a 2 × 2 contingency table (low-risk: absence of a shunt and Cognard types I–IIa; high-risk: Cognard types IIb, III, IV, and V) and on a 3-tier modified scale (comprising absence of a shunt; Cognard types I–IIa; and Cognard types IIb, III, IV, and V). The Cohen κ coefficient was calculated using quadratic weighting (for bleeding-risk grading with the 3-tier modified scale). The 95% confidence intervals for κ were estimated with the bootstrap method. κ statistics were interpreted as suggested by Landis and Koch (κ < 0, poor agreement; 0.01–0.20, slight agreement; 0.21–0.40, fair agreement; 0.41–0.60, moderate agreement; 0.61–0.80, substantial agreement; and 0.81–1, almost perfect agreement).

The binary decision regarding the presence of a residual/recurrent DAVF and a residual high-bleeding-risk DAVF (low

risk: absence of a shunt and Cognard types I–IIa; high risk: Cognard types IIb, III, IV, and V) was used to determine the diagnostic performance of 4D-MRA (sensitivity, specificity, positive predictive value, negative predictive value, the area under the ROC curve), and 95% confidence intervals were estimated with generalized estimating equations.

All statistical analyses were performed using STATA software (STATA/MP 16.0; StataCorp).

RESULTS
We included 51 examination pairs (4D-MRA and DSA within 6 months) for 44 patients with a median age of 65 years (range, 25–81 years). No examination (neither 4D-MRA nor DSA) was included >1 time. Nineteen (43%) of the 44 patients were women. Pretreatment DAVF grading was as follows—type I: n = 1 (2.3%), type IIa: n = 2 (4.6%), type IIb: n = 13 (29.5%), type IIa + b: n = 0 (0%), type III: n = 13 (29.5%), type IV: n = 12 (27.3%), and type V: n = 3 (6.8%). Thirty-nine (88.6%) patients underwent 1 embolization session, and 5 patients (11.4%) underwent 2 sessions. The corresponding flowchart is shown in Fig 1. The median interval between 4D-MRA and DSA was 49 days (range, 0–155 days).

4D-MRA was performed before DSA in 31 (70.4%) examination pairs. The median interval between DAVF treatment and the first examination was 124 days (range, 2–730 days). The DSA images yielded the following results—no residual/recurrent DAVF: 29/51 (56.9%), type I: n = 4 (7.9%), type IIa: n = 4 (7.9%), type IIb: n = 1 (1.9%), type IIa + b: n = 0 (0%), type III: n = 11 (21.6%), type IV: n = 1 (1.9%), and type V residual/recurrent DAVF: n = 1 (1.9%). Twelve examination pairs were obtained from 5 patients: After the first follow-up (n = 5), 4 examination pairs were obtained after a new treatment and 3 later in the follow-up of the first treatment.

4D-MRA Image Quality
After reaching a consensus, all images were given a minimum score of 1. The median quality score was 3. One (1.9%) 4D-MRA examination scored 1, seven (13.7%) scored 2, and 43 (84.4%) scored 3 on the 4-point grading scale, respectively.

4D-MRA Interobserver Agreement
One reader assigned 1 examination a score of zero (no vascular study possible). Fifty examinations were assessed for interobserver agreement. Interobserver agreement was considered substantial for residual/recurrent DAVF detection, with an agreement of 92% and \( \kappa = 0.8 \) (95% CI, 0.6–1). Disagreement among readers (readers 1 and 2) is shown in Table 1. Interobserver agreement was considered substantial in terms of the ability to detect a fistula at risk of hemorrhage, with an agreement of 92% and \( \kappa = 0.8 \) (95% CI, 0.5–1) in a 2 × 2 contingency table (low-risk: absence of a shunt and types I–IIa; high-risk: types IIb, III, IV, and V) and an agreement of 92% and \( \kappa = 0.8 \) (95% CI, 0.8–0.9) on a 3-tier modified scale (comprising absence of a shunt; types I–IIa; and IIb, III, IV, and V).

Intermodality Agreement
After reaching a 4D-MRA reading consensus, 51 comparisons were available. Table 2 provides the results for the 2 modalities. Disagreement between readers 1 and 2 is shown in Table 3.

Intermodality agreement was considered substantial for residual/recurrent DAVF detection, with an agreement of 82.4% and \( \kappa = 0.6 \) (95% CI, 0.4–0.8). Intermodality agreement
was considered moderate in terms of the ability to detect a fistula at risk of hemorrhage, with an agreement of 84.3% and $\kappa = 0.6$ (95% CI, 0.3–0.8) in a 2x2 contingency table (low-risk: absence of a shunt and types I–IIa; high-risk: types IIb, III, IV, and V) and an agreement of 83.3% and $\kappa = 0.6$ (95% CI, 0.5–0.7) on a 3-tier modified scale (comprising absence of a shunt; types I–IIa; types IIb, III, IV, and V).

**Diagnostic Value of 4D-MRA Compared with DSA**

The diagnostic accuracy of 4D-MRA in terms of residual/recurrent DAVF detection yielded a sensitivity of 63.6% (95% CI, 40.7%–82.8%), specificity of 96.6% (95% CI, 82.2%–99.9%), positive predictive value of 93.3% (95% CI, 68.1%–99.8%), and negative predictive value of 77.8% (95% CI, 60.8%–89.9%). The area under curve score was 0.8 (95% CI, 0.7–0.9).

The diagnostic accuracy of 4D-MRA in terms of bleeding-risk grading yielded a sensitivity of 50% (95% CI, 23%–77%), specificity of 97.3% (95% CI, 85.8%–99.9%), positive predictive value of 87.5% (95% CI, 47.3%–99.7%), and negative predictive value of 83.7% (95% CI, 69.3%–93.2%). The area under the curve score was 0.7 (95% CI, 0.6–0.8).

**Retrospective Review of Intermodality Disagreement**

As described in Table 3, intermodality disagreement involved 8 false-negatives and 1 false-positive result. There were several

---

**Table 2: Contingency table of residual/recurrent DAVF grading according to technique (4D-MRA and DSA)**

<table>
<thead>
<tr>
<th>DSA</th>
<th>4D-MRA</th>
<th>No Shunt</th>
<th>Type I&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Type II&lt;sup&gt;a,b&lt;/sup&gt;</th>
<th>Type IIb&lt;sup&gt;c&lt;/sup&gt;</th>
<th>Type IIa+b&lt;sup&gt;c&lt;/sup&gt;</th>
<th>Type III&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Type IV&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Type V&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>No shunt</td>
<td>28</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Type I&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Type IIa&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Type IIb&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Type IIa + b&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Type III&lt;sup&gt;a&lt;/sup&gt;</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Type IV&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Type V&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

<sup>a</sup> Consensus grading according to Cognard et al. 5
<sup>b</sup> Low bleeding risk.
<sup>c</sup> High bleeding risk.

**Table 3: Intermodality discrepancy in residual/recurrent dural arteriovenous fistula detection and classification**

<table>
<thead>
<tr>
<th>Location</th>
<th>Pretreatment Grading</th>
<th>4D-MRA/DSA Interval (Days)</th>
<th>DSA Grading</th>
<th>4D-MRA Consensus Grading</th>
<th>4D-MRA Reader Disagreement (Yes/No)</th>
<th>Year</th>
<th>4D-MRA Consensus Quality Score</th>
<th>Possible Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parasagittal right</td>
<td>III</td>
<td>65</td>
<td>IV</td>
<td>0</td>
<td>No</td>
<td>2010</td>
<td>3</td>
<td>Confusion between occipital artery and a cortical vein</td>
</tr>
<tr>
<td>Cavernous sinus right</td>
<td>III</td>
<td>59</td>
<td>III</td>
<td>0</td>
<td>No</td>
<td>2015</td>
<td>2</td>
<td>Cortical vein visible but missed by 4D-MRA readers</td>
</tr>
<tr>
<td>Transverse sinus left</td>
<td>IIb</td>
<td>112</td>
<td>I</td>
<td>0</td>
<td>No</td>
<td>2017</td>
<td>2</td>
<td>Artery and vein overlay</td>
</tr>
<tr>
<td>SSS</td>
<td>IIb</td>
<td>129</td>
<td>0</td>
<td>IIA + b</td>
<td>No</td>
<td>2012</td>
<td>3</td>
<td>Early drainage due to a meningioma</td>
</tr>
<tr>
<td>Cavernous sinus left</td>
<td>III</td>
<td>0</td>
<td>III</td>
<td>0</td>
<td>No</td>
<td>2015</td>
<td>3</td>
<td>Cortical vein visible but missed by 4D-MRA readers</td>
</tr>
<tr>
<td>Posterior fossa right</td>
<td>IV</td>
<td>43</td>
<td>III</td>
<td>0</td>
<td>No</td>
<td>2009</td>
<td>3</td>
<td>Early opacification of all dural sinuses; shunt missed due to misinterpretation of time sequence in 4D-MRA</td>
</tr>
<tr>
<td>Sigmoid sinus left</td>
<td>III</td>
<td>2</td>
<td>IIa</td>
<td>0</td>
<td>No</td>
<td>2011</td>
<td>2</td>
<td>Cortical vein visible but missed by 4D-MRA readers</td>
</tr>
<tr>
<td>Medulla</td>
<td>V</td>
<td>3</td>
<td>V</td>
<td>0</td>
<td>Yes (III/0)</td>
<td>2011</td>
<td>3</td>
<td>Not visible in the FOV Cortical vein visible but missed by 4D-MRA readers</td>
</tr>
<tr>
<td>Parieto-occipital left</td>
<td>III</td>
<td>85</td>
<td>III</td>
<td>0</td>
<td>No</td>
<td>2018</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> Grading according to Cognard et al. 5

---

Note:—SSS indicates superior sagittal sinus.
DAVF locations: supra- or infra tentorial, near the midsagittal plane, or more laterally. Figs 2 and 3 provide examples of a true-positive result and a false-negative result of 4D-MRA. Only 1 intermodality disagreement was also an interobserver disagreement. The false-positive case was due to a concomitant condition (early venous drainage due to a meningioma in the vicinity of the DAVF). Six of the 8 false-negative cases involved types III, IV, or V DAVFs, ie, DAVFs with cortical (small) veins. In 4 cases, the cortical vein was shown to be retrospectively present but was missed by all 3 readers.

**DISCUSSION**

This study assessed the diagnostic accuracy of 4D-MRA at 3T for detecting any recurrent/residual shunts in treated DAVFs. The sensitivity and specificity of the technique were, respectively, 63.6% (95% CI, 40.7%–82.8%) and 96.6% (95% CI, 82.2%–99.9%), with substantial intermodality agreement compared with DSA, which yielded agreement of 82.4% and $\kappa = 0.6$ (95% CI, 0.4%–0.8%).

4D contrast-enhanced MRA is widely used to detect, characterize, and monitor brain vascular malformations and conditions, especially brain arteriovenous malformations. Previous studies reported the diagnostic performance of 4D-MRA for detection and grading of DAVFs. Contrary to brain arteriovenous malformations, only a few studies documented treated DAVFs, and they concerned limited numbers of patients. The value of 4D-MRA in posttreatment follow-up is, therefore, currently not well-defined. Meckel et al evaluated the diagnostic performance of MRA using a time-resolved 3D contrast-enhanced technique with 18 examination pairs (9 in a diagnosis group and 9 in a posttreatment follow-up group). On initial diagnosis, both readers identified signs indicative of a DAVF in all 9 cases of angiographically proved fistulas. In the follow-up group (postembolization or surgery), both readers were able to differentiate between complete occlusion of a fistula and a patent residual fistula. However, DAVF occlusion was complete in 5 of the 9 patients. The readers could also use subtracted volumes in addition to 3-plane MIP images, which may have improved diagnostic accuracy.

Bink et al reported diagnostic accuracy with 3T MR imaging, with sensitivities and specificities ranging from 84% to 100% for 3 readers tasked with detecting DAVFs in 38 patients (19 with DAVFs and 19 without). The readers assessed 4D-MRA in addition to 3D-TOF-MRA and 3D-MPRAGE. One patient had undergone endovascular therapy, and 1 patient had undergone surgical closure. In a consensus reading, Ertl et al reported excellent intermodality agreement ($\kappa = 1$) for the pretreatment Cognard classification of lateral DAVFs in 24 patients using additional anatomic images such as TOF-MRA, contrast-enhanced T1-, axial T2-, and axial T2*-weighted images. However, there were no type III DAVFs and just 3 type IV DAVFs according to the Cognard classification. Farb et al compared 4D-MRA at 3T with DSA for the diagnosis and classification of DAVFs in 42 cases, which included surveillance of a previously cured fistula in 15 cases. In 93% (39/42) of DAVFs, 3 readers were unanimous and correct in identifying or excluding them. However, all examinations performed for surveillance were negative for DSA, thus limiting the generalizability of the results in this population.
Unlike previous studies, we chose to assess 4D-MRA alone without additional morphologic images. This could partly explain the lower performance in this context. Also, posttherapeutic changes, such as embolization product artifacts or anatomic changes, could partly explain these results. Another explanation might be the higher proportion of Cognard type III and IV DAVFs in our study compared with that of Ertl et al. Indeed, direct drainage into a cortical vein might reduce DAVF detection with 4D-MRA.

The sensitivity and specificity of the technique in terms of the ability to detect a fistula at risk of hemorrhage was, respectively, 50% (95% CI, 23.3%–77%) and 97.3% (95% CI, 85.8%–99.9%), with an agreement of 84.3% and $\kappa = 0.6$ (95% CI, 0.3–0.8) in a 2 x 2 contingency table (low-risk: absence of a shunt and types I–IIa; high-risk: types IIb, III, IV, and V) and an agreement of 83.3% and $\kappa = 0.6$ (95% CI, 0.5–0.7) on a 3-tier modified scale (comprising absence of a shunt; types I–IIa; and IIb, III, IV, and V). Detecting the bleeding risk of a residual/recurrent DAVF is crucial in determining further treatment (false-negative rate of 0.5). Six of 8 false-negatives on 4D-MRA were types III–V DAVFs. We note that the cortical vein was shown to be retrospectively present but was missed by all 3 readers in 4 cases. For 1 patient, the cortical veins were not included in the FOV. In addition to this acquisition defect, discrepancies could be explained by the lack of spatial or temporal resolution. Also, we might speculate that 3-plane MIP image reading was perhaps not the optimal method. Multiplanner, thin MIP reconstructions could help to alleviate confusion between arteries and veins, though the existing literature on the method for reading 4D-MRA images for DAVF (thick MIP, thin MIP, MPR) is limited.

Interobserver agreement was considered substantial for residual/recurrent DAVF detection, with an agreement of 92% and $\kappa = 0.8$ (95% CI, 0.6–1). Farb et al reported agreement among 3 readers of 0.94 [SD, 0.04] ($P < .001$). In our study, 4 of 6 cases of disagreement involved type III DAVFs, ie, DAVFs with direct drainage into a cortical vein. All except 1 disagreement involved high-quality (score = 3) 4D-MRA images.

**Limitations**

Limitations of our study include its retrospective design and the relatively small number of patients. However, to the best of our knowledge, this is the largest series of patients in the particular case of postembolization evaluation. Indeed, DAVF is a rare disease, and we focused on patients with embolized DAVFs who had undergone DSA and 4D-MRA within a 6-month interval during their follow-up, and this focused the number of eligible patients, possibly resulting in a selection bias because patients with negative findings on DSA or who were asymptomatic but with a residual low-risk DAVF with DSA were less likely to benefit from both modalities within 6 months. The reason for this focus was because it is the first line of treatment for most DAVFs, and surgical treatment may involve the use of materials that can cause artifacts. Second, different 4D-MRA techniques were used due to the study length and the 2 centers involved. Although Lin et al reported a trend toward better performance in newer MR imaging studies, in our cases, intermodality discrepancies involved recent and older examinations, as shown in Table 3. Furthermore, we graded image quality to overcome this limitation. Third, we read only the 4D-MRA images without any other sequences. This may seem artificial, but it was essential for assessing the diagnostic accuracy of the technique (4D-MRA). Fourth, the statistical distribution of the DAVF types based on the Cognard classification with a higher proportion of true-negative results (DSA, 0; 4D-MRA, 0) was expected but may have influenced the $\kappa$ values.

As previously shown, the use of consensus reading for 4D-MRA in our study improved the diagnostic accuracy and might, therefore, be recommended. Also, several publications have described novel tools that can further improve 4D-MRA efficacy, opening up new prospects for DAVF assessment before and after treatment. Indeed, venous arterial spin-labeling has shown high sensitivity and specificity in detecting dural arteriovenous fistulas, and the novel temporal spatial acceleration method, HYPRFlow, has also been reported to provide accurate delineation of DAVF vasculature.

**CONCLUSIONS**

4D-MRA is a useful noninvasive technique for the follow-up of treated DAVFs. However, given its current limitations, it is not sufficient to confirm an effective cure but can be used as a diagnostic confirmation test. DSA remains mandatory for ensuring optimum bleeding-risk assessment in cases of residual/recurrent DAVF.

**REFERENCES**


